Search
                    Ketamine Treatment Options in Washington
A collection of 13 research studies where Ketamine is the interventional treatment. These studies are located in the Washington, United States. Ketamine is used for conditions such as Pain, Major Depressive Disorder and Depression.
            1 - 12 of 13
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002
                                
            
            
        Not Yet Recruiting
                            
            
                This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design.
Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                07/03/2025
            
            Locations: Madigan Army Medical Center, Joint Base Lewis McChord, Washington         
        
        
            Conditions: Post Traumatic Stress Disorder
        
            
        
    
                
                                    Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain
                                
            
            
        Active Not Recruiting
                            
            
                The study utilizes a 3-arm placebo-controlled RCT to study the effectiveness of ketamine in reducing chronic post-mastectomy pain. Participants randomized to the first arm will receive a 0.35 mg/kg dose after induction, followed by a 0.25 mg/kg/hr infusion during surgery (up to a maximum of 6 hours) and continued for 2 hours postoperatively. Participants in the second arm will receive a single dose of 0.6 mg/kg of ketamine in the post-anesthesia care unit, and the final group will serve as the c...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                06/24/2025
            
            Locations: University of Washington Medical Center, Seattle, Washington         
        
        
            Conditions: Chronic Postsurgical Pain
        
            
        
    
                
                                    A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
                                
            
            
        Completed
                            
            
                The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 64 years
            Trial Updated:
                04/25/2025
            
            Locations: Not set, Bothell, Washington         
        
        
            Conditions: Treatment-resistant Depression
        
            
        
    
                
                                    A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
                                
            
            
        Completed
                            
            
                The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.             
        
        
    Gender:
                ALL
            Ages:
                65 years and above
            Trial Updated:
                04/25/2025
            
            Locations: Not set, Richland, Washington         
        
        
            Conditions: Depressive Disorder, Treatment-Resistant
        
            
        
    
                
                                    A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
                                
            
            
        Completed
                            
            
                The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/25/2025
            
            Locations: Not set, Richland, Washington         
        
        
            Conditions: Treatment-resistant Depression
        
            
        
    
                
                                    Morphine or Ketamine for Analgesia
                                
            
            
        Not Yet Recruiting
                            
            
                Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 6 years and 17 years
            Trial Updated:
                02/17/2025
            
            Locations: Seattle Children's Hospital, Seattle, Washington         
        
        
            Conditions: Abdominal Pain, Isolated Extremity Fracture, Pain, Pediatrics
        
            
        
    
                
                                    A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
                                
            
            
        Completed
                            
            
                Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy to promote emotional wellbeing. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health. We predicted that clients would experience lasting reductions in psychological distress over time, such as depression, anxiety, and post tr...  Read More             
        
        
    Gender:
                ALL
            Ages:
                19 years and above
            Trial Updated:
                02/22/2024
            
            Locations: Seattle Centre, Seattle, Washington         
        
        
            
        
    
                
                                    Ketamine Versus Fentanyl for Surgical Abortions
                                
            
            
        Completed
                            
            
                Ketamine is commonly used for procedural sedation and analgesia. It is widely used for trauma cases in the emergency department and is considered a superior agent in the outpatient setting due to its lack of respiratory and cardiovascular depression. In chronic opioid users, ketamine decreases acute pain and reduces postoperative opioid consumption. Few studies have examined the use of ketamine for surgical abortions. Previous studies found significant rates of emergence phenomena; however, this...  Read More             
        
        
    Gender:
                FEMALE
            Ages:
                14 years and above
            Trial Updated:
                03/22/2022
            
            Locations: Cedar River Clinic, Renton, Washington         
        
        
            Conditions: Abortion in First Trimester, Pain, Procedural, Opioid Use
        
            
        
    
                
                                    Ketamine Anesthesia for Improvement of Depression in ECT
                                
            
            
        Completed
                            
            
                The purpose of this prospective randomized clinical trial is to determine if patients receiving ketamine as a part of general anesthesia during electroconvulsive therapy (ECT) rather than standard of care will have improvement in symptoms of depression after a course of ECT treatments. The investigators hypothesize that utilization of ketamine for induction of general anesthesia during ECT treatments will improve symptoms of depression better than standard care.
This study is ONLY open to patie...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                06/01/2018
            
            Locations: VA Puget Sound Health Care System, Seattle, Washington         
        
        
            Conditions: Major Depressive Disorder
        
            
        
    
                
                                    Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
                                
            
            
        Completed
                            
            
                RATIONALE: Baclofen-amitriptyline-ketamine (BAK) gel may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether BAK gel is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy .
PURPOSE: This randomized phase III trial is studying BAK gel to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/25/2017
            
            Locations: Southwest Washington Medical Center Cancer Center, Vancouver, Washington         
        
        
            Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
        
            
        
    
                
                                    Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
                                
            
            
        Completed
                            
            
                RATIONALE: Topical cream containing amitriptyline and ketamine may help relieve pain, numbness, tingling, and other symptoms of peripheral neuropathy. It is not yet known whether topical amitriptyline and ketamine cream is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy.
PURPOSE: This randomized phase III trial is studying the side effects and how well topical amitriptyline and ketamine cream work compared with a placebo in treating peripheral neuropathy c...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 120 years
            Trial Updated:
                10/13/2015
            
            Locations: CCOP - Virginia Mason Research Center, Seattle, Washington  +1 locations         
        
        
            Conditions: Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
        
            
        
    
                
                                    Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting
                                
            
            
        Unknown
                            
            
                This project is a pilot study to evaluate the analgesic and opioid-sparing effects of ketamine in an ultra-low dose oral formulation as a novel intervention for treatment of chronic non-cancer pain in opioid-tolerant patients in the primary care outpatient setting.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/24/2015
            
            Locations: Pioneer Family Practice, Lacey, Washington         
        
        
            Conditions: Chronic Pain
        
            
        
    